chartexchange

Harrow Closes Acquisition of TYRVAYA®

GlobeNewswire Inc. | Oct 5, 2026 7:00 AM EDT

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise

Read original article